Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ESIDRIX vs ANHYDRON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption, leading to increased diuresis and decreased extracellular volume.
Inhibits the sodium-potassium-2 chloride (Na-K-2Cl) cotransporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.
Hypertension,Edema associated with congestive heart failure, cirrhosis, or renal disease
Edema associated with congestive heart failure, cirrhosis of the liver, and renal disease,Hypertension (off-label use)
25-50 mg orally once daily; may increase to 100 mg once daily or 50 mg twice daily for resistant edema.
Oral: 25-100 mg once daily in the morning, or 50-100 mg every other day; maximum 200 mg/day.
Terminal elimination half-life is approximately 10-15 hours (mean 12 hours); clinical context: half-life prolonged in renal impairment, requiring dose adjustment.
Terminal elimination half-life is 60-90 minutes, prolonged in renal impairment (up to 24 hours).
Not significantly metabolized; primarily excreted unchanged in urine.
Partially metabolized by the liver; primarily excreted unchanged in urine.
Renal: approximately 70% excreted unchanged in urine; biliary/fecal: less than 10%.
Renal: ~60% unchanged; biliary/fecal: ~40% as metabolites and unchanged drug.
Approximately 75% bound to plasma proteins, primarily albumin.
95% bound, primarily to albumin.
Vd is 0.1-0.2 L/kg; indicates limited extravascular distribution consistent with hydrophilic properties.
0.2-0.3 L/kg, reflecting distribution primarily in extracellular fluid.
Oral: bioavailability is approximately 80-90%.
Oral: ~65% (range 50-80%) due to first-pass metabolism.
GFR 25-50 m L/min: administer every 12 hours; GFR 10-25 m L/min: administer every 24 hours; GFR <10 m L/min: not recommended due to ineffectiveness.
GFR 10-50 m L/min: 50 mg every 12 hours. GFR <10 m L/min: 50 mg every 24 hours or not recommended.
Child-Pugh Class B or C: reduce dose by 50% or use with caution due to risk of electrolyte disturbances and hepatic encephalopathy.
Mild to moderate hepatic impairment (Child-Pugh A or B): no adjustment. Severe hepatic impairment (Child-Pugh C): avoid use.
1-2 mg/kg orally once daily; maximum 50 mg/day.
1-2 mg/kg/dose once daily; maximum 100 mg/day.
Start at 12.5-25 mg orally once daily; monitor electrolytes and renal function; adjust dose based on response and tolerability.
Start at 12.5-25 mg once daily; titrate slowly due to risk of hypotension and electrolyte imbalance.
Not applicable
No FDA black box warning.
Hypokalemia,Hyperuricemia,Hypomagnesemia,Hypercalcemia,Orthostatic hypotension,Photosensitivity,Systemic lupus erythematosus exacerbation,Sulfonamide allergy cross-sensitivity
Electrolyte imbalance (hypokalemia, hyponatremia, hypochloremia),Dehydration and hypotension,Ototoxicity (especially with rapid IV administration or renal impairment),Hyperuricemia and gout,Sulfonamide cross-sensitivity in sulfa-allergic patients
Anuria,Hypersensitivity to hydrochlorothiazide or sulfonamide-derived drugs
Anuria,Severe renal failure,Hepatic coma or pre-coma,Severe electrolyte depletion,Hypersensitivity to sulfonamides
Avoid high-sodium foods as they reduce antihypertensive efficacy. Limit potassium-rich foods (bananas, oranges) only if directed; hypokalemia risk is counteracted by high intake. Grapefruit juice may decrease HCTZ absorption; separate intake by 4 hours. Reduce alcohol intake to prevent additive hypotension.
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, spinach) as hyperkalemia may occur. Limit salt substitutes containing potassium. Grapefruit juice may increase drug absorption; avoid concurrent use. Alcohol may enhance orthostatic hypotension.
First trimester: Limited human data; potential for fetal bradycardia and hypotension. Second and third trimesters: Increased risk of fetal hypotension, renal dysfunction, oligohydramnios, and skull ossification delays.
Cyclothiazide (ANHYDRON) is a thiazide diuretic. Use in pregnancy is generally avoided due to potential adverse effects. First trimester: limited data, but thiazides have been associated with an increased risk of congenital anomalies in some studies, including cleft lip/palate and cardiac defects. Second and third trimesters: can cause fetal or neonatal jaundice, thrombocytopenia, electrolyte disturbances, and possibly intrauterine growth restriction. Crosses the placenta. Use only if clearly needed for maternal conditions like hypertension or edema.
Excreted in human milk; M/P ratio unknown. Due to potential for adverse effects (e.g., electrolyte disturbances), caution advised; avoid if possible, especially in preterm infants.
Cyclothiazide is excreted into human breast milk. The milk-to-plasma ratio is not well defined for cyclothiazide but for thiazides generally is around 0.5-1.0. May suppress lactation. Potential for infant adverse effects (e.g., electrolyte disturbances, thrombocytopenia). Use caution in breastfeeding; alternatives are preferred.
No routine dose adjustment recommended based on pharmacokinetic changes; however, use lowest effective dose due to altered volume of distribution and clearance.
Pharmacokinetic changes in pregnancy (increased plasma volume, renal blood flow, and GFR) may reduce effectiveness of thiazides. No specific dosing adjustment guidelines for cyclothiazide; however, if used, start at lowest effective dose and titrate based on response. Typical adult dose: 2 mg once daily; may adjust to 1-4 mg. Monitor for hypotension and electrolyte imbalances. Avoid in preeclampsia due to decreased placental perfusion.
Hydrochlorothiazide (HCTZ) in Esidrix may unmask diabetes (hyperglycemia), exacerbate gout (hyperuricemia), and cause hypokalemia (especially at high doses). Monitor electrolytes and renal function. Sunset yellow dye in tablets may cause allergic reactions in aspirin-sensitive patients.
ANHYDRON (cyclothiazide) is a thiazide-like diuretic used for hypertension and edema. Monitor serum potassium and glucose levels; hypokalemia and hyperglycemia are common. Use with caution in renal impairment (Cr Cl <30 m L/min). Avoid in patients with anuria or sulfonamide allergy.
Take in the morning to avoid nocturia.,Avoid prolonged sun exposure; use sunscreen as photosensitivity may occur.,Report signs of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat.,May increase blood sugar; monitor if diabetic.,Do not take with alcohol or other blood pressure medications without consulting doctor.
Take exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,May cause dizziness or lightheadedness; rise slowly from sitting or lying down.,Avoid prolonged sun exposure; use sunscreen as photosensitivity may occur.,Report signs of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat.,Do not stop abruptly without consulting your doctor; gradual dose reduction may be needed.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ESIDRIX vs ANHYDRON, answered by our medical review team.
ESIDRIX is a Thiazide Diuretic that works by Thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption, leading to increased diuresis and decreased extracellular volume.. ANHYDRON is a Thiazide Diuretic that works by Inhibits the sodium-potassium-2 chloride (Na-K-2Cl) cotransporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ESIDRIX and ANHYDRON depend on the specific clinical indication. These are both Thiazide Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ESIDRIX is: 25-50 mg orally once daily; may increase to 100 mg once daily or 50 mg twice daily for resistant edema.. The standard adult dose of ANHYDRON is: Oral: 25-100 mg once daily in the morning, or 50-100 mg every other day; maximum 200 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ESIDRIX and ANHYDRON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ESIDRIX is classified as Category C. First trimester: Limited human data; potential for fetal bradycardia and hypotension. Second and third trimesters: Increased risk of fetal hypotension, renal dysfunction, oligohydr. ANHYDRON is classified as Category C. Cyclothiazide (ANHYDRON) is a thiazide diuretic. Use in pregnancy is generally avoided due to potential adverse effects. First trimester: limited data, but thiazides have been asso. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.